The treatment effects and cardiovascular events of high-dose intravenous iron for hemodialysis patients with renal anemia: A systematic review and meta-analysis
Restricted accessReview articleFirst published online June, 2024
The treatment effects and cardiovascular events of high-dose intravenous iron for hemodialysis patients with renal anemia: A systematic review and meta-analysis
Hemodialysis patients are common to have renal anemia in the nephrology practice. For the renal anemia, the high-dose iron from the intravenous route is an important treatment option. We can understand the treatment effects and cardiovascular events of high-dose intravenous iron reviewing the randomized clinical trials.
Methods
We compared the high-dose and low-dose iron treatments to find if the high-dose intravenous iron can influence the hematological parameters more significantly than the low-dose iron. The cardiovascular events were also analyzed for the high-dose iron treatment. Six studies with a total of 2422 renal anemia patients under hemodialysis were enrolled. We focused the outcomes of hemoglobin, transferrin saturation percentage, ferritin, erythropoietin dose, and cardiovascular events.
Results
The high-dose intravenous iron might be associated with a greater number of ferritin, transferrin saturation percentage, and hemoglobin. In addition, the erythropoietin dose was less needed to maintain the ideal hemoglobin range in the high-dose intravenous iron group.
Conclusions
In current meta-analysis, the high-dose intravenous iron might show the superior effects on the ferritin, transferrin saturation percentage, and hemoglobin levels and needed dose of erythropoietin when compared to low-dose iron treatment.
SalimSACheungpasitpornWElmaraezyA, et al.Infectious complications and mortality associated with the use of IV iron therapy: a systematic review and meta-analysis. Int Urol Nephrol2019; 51: 1855–1865.
2.
BieleszBLorenzMMonteforteR, et al.Comparison of iron dosing strategies in patients undergoing long-term hemodialysis: a randomized controlled trial. Clin J Am Soc Nephrol2021; 16: 1512–1521.
3.
LiXKshirsagarAVBrookhartMA. Safety of intravenous iron in hemodialysis patients. Hemodial Int2017; 21: S93–S103.
4.
MacdougallICWhiteCAnkerSD, et al.Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med2019; 380: 447–458.
5.
MacdougallICStraussWEDahlNV, et al.Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial. Clin Nephrol2019; 91: 237–245.
6.
SchillerBBhatPSharmaA. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther2014; 36: 70–83.
7.
WanLZhangD. Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients. Int Urol Nephrol2018; 50: 1511–1518.
8.
MiskulinDCTangriNBandeen-RocheK, et al.Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol2014; 9: 1930–1939.
9.
Zununi VahedSAhmadianEHejazianSM, et al.The impact of intravenous iron supplementation on hematinic parameters and erythropoietin requirements in hemodialysis patients. Adv Ther2021; 38: 4413–4424.
10.
KoschMBahnerUBettgerH, et al.A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant2001; 16: 1239–1244.
11.
KnoblochKYoonUVogtPM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Cranio-Maxillofac Surg2011; 39: 91–92.
12.
BesarabAAminNAhsanM, et al.Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol2000; 11: 530–538.
13.
BolanosLCastroPFalconTG, et al.Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol2002; 22: 67–72.
14.
KapoianTO'MaraNBSinghAK, et al.Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol2008; 19: 372–379.
15.
GanguliAKohliHSKhullarM,et al.Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Renal Fail. 2009; 31: 106–110.
16.
Del VecchioLLonghiSLocatelliF. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J2016; 9: 260–267.
17.
NevenEDe SchutterTMBehetsGJ, et al.Iron and vascular calcification. Is there a link?Nephrol Dial Transplant2011; 26: 1137–1145.
18.
MacdougallICBircherAJEckardtKU, et al.Iron management in chronic kidney disease: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) controversies conference. Kidney Int2016; 89: 28–39.
19.
HougenICollisterDBourrierM, et al.Safety of intravenous iron in dialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol2018; 13: 457–467.
20.
Del VecchioLEkartRFerroCJ, et al.Intravenous iron therapy and the cardiovascular system: risks and benefits. Clin Kidney J2021; 14: 1067–1076.
21.
DrozdzMWeigertASilvaF, et al.Achievement of renal anemia KDIGO targets by two different clinical strategies—a European hemodialysis multicenter analysis. BMC Nephrol2019; 20: 5.
22.
GawedaAEBhatPMaglinteGA, et al.TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients. Hemodial Int2014; 18: 38–46.
23.
KuraganoTJokiNHaseH, et al.Low transferrin saturation (TSAT) and high ferritin levels are significant predictors for cerebrovascular and cardiovascular disease and death in maintenance hemodialysis patients. PLoS One2020; 15: e0236277.
24.
WishJB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol2006; 1: S4–S8.
25.
YuPHLinMYChiuYW, et al.Low serum iron is associated with anemia in CKD stage 1-4 patients with normal transferrin saturations. Sci Rep2021; 11: 8343.
26.
LocatelliFNissensonARBarrettBJ, et al.Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from kidney disease: improving Global Outcomes (KDIGO). Kidney Int2008; 74: 1237–1240.
27.
BailieGRLarkinaMGoodkinDA, et al.Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant2013; 28: 2570–2579.
28.
LacquanitiAPasqualettiPToccoTCD, et al.Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up. Kidney Res Clin Pract2020; 39: 334–343.
29.
LiHWangSX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif2008; 26: 151–156.
30.
KuoKLHungSCTsengWC, et al.Association of anemia and iron parameters with mortality among patients undergoing prevalent hemodialysis in Taiwan: the AIM - HD study. J Am Heart Assoc2018; 7: e009206.
